Bintrafusp Alfa in Previously Treated Patients With R/M Non-keratinizing NPC

Histologically or cytologically confirmed non-keratinizing differentiated (World Health Organization WHO Type II) or undifferentiated (WHO Type III) nasopharyngeal carcinoma (NPC) that has recurred at regional or / and distant sitesMeasurable disease according to the RECIST criteria (version 1.1) for the evaluation of measurable disease Received one or more lines of chemotherapy, which must include prior treatment with a platinum agent either for the treatment of metastatic or recurrent disease Experienced progression of disease within 6 months following completion of a platinum-based combination therapy as part of (neo)-adjuvant therapy Male or female subjects with age: 18-79 years old Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2 No prior immunotherapy Written informed consent obtained for clinical trial participation and providing archival tumor tissue, if available Females of childbearing potential or non-sterilized male who are sexually active must use a highly effective method of contraception Females of childbearing potential must have negative serum or urine pregnancy test Have life expectancy ≥ 3 months Adequate organ function as defined as: Absolute neutrophil count ≥ 1.5 x 10^9/L, Platelet count ≥ 100 x 10^9/L, Hemoglobin >= 8.0 g/dL, Serum alanine aminotransferase ([ALT]; serum glutamate-pyruvate transferase [SGPT]), or serum aspartate aminotransferase [AST] where available at the center) < 2.5 x upper limit of normal (ULN), OR < 5 x ULN in the presence of liver metastases Serum total bilirubin < 2 x ULN Serum creatinine < 1.5 x ULN